The relationship between pharmaceutical companies and medical professionals has become too close for comfort, say many experts. They fear that the situation can breed conflicts of interest that lead to the creation of new, poorly defined concepts of illnesses—so called 'disease mongering'. The problem is a growing one, according to Ray Moynihan, honorary lecturer on topics such as 'medicine and the media' at the School of Medicine and Public Health at the University of Newcastle in Callaghan, Australia and co-author of the book Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All into Patients. Genevive Bjorn talked with Moynihan, who helped organize the first world conference on disease mongering, about how this phenomenon affects health priorities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bjorn, G. Straight talk with...Ray Moynihan. Nat Med 14, 1142–1143 (2008). https://doi.org/10.1038/nm1108-1142
Issue Date:
DOI: https://doi.org/10.1038/nm1108-1142
This article is cited by
-
Disease mongering is a myth
Nature Medicine (2009)